When was Kailera founded?

Kailera was founded in 2024 and raised its 1st funding round within a year of its incorporation.

Where is Kailera located?

Kailera is headquartered in Waltham, United States.

Who is the current CEO of Kailera?

Ron Renaud of Kailera. They have also founded 1 company.

How many employees does Kailera have?

As of Jul 31, 2026, the latest employee count at Kailera is 181.

Is Kailera a funded company?

Kailera is a funded company, having raised a total of $1B across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 01, 2024.

When was the latest funding round of Kailera?

Kailera's latest funding was a $***** Series B round on Oct 14, 2025, with participation from 13 investors.

Where does Kailera rank among its competitors?

Kailera ranks 3rd amongst 415 active competitors, of which 164 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Lexicon Pharmaceuticals, which secured $55.7M in Feb, 2026.

Who are the top competitors of Kailera?

Kailera's top competitors include Sana Biotechnology, Adocia and Assembly Biosciences. Among them, Lexicon Pharmaceuticals secured the most recent funding round in February, 2026.

Kailera - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapies for treating obesity and related conditions. It offers a pipeline of drug candidates which include KAI-9531 a GLP-1/GIP receptor dual agonist formulated as an injectable peptide, KAI-7535 is an oral small molecule, KAI-9531 is a GLP-1/GIP receptor, and KAI-9531 is a GLP-1/GIP receptor for the treatment of obesity and type 2 diabetes.

Website: kailera.com
Social

Key Metrics

Founded Year

2024

Location

Waltham, United States

Stage

Public

Total Funding

$1B in 2 rounds

Latest Funding Round

Series B, Oct 14, 2025, $*****

Investors

Atlas Venture & 13 more

Ranked

3^rd among 415 active competitors

Employee Count

181 as on Jul 31, 2026

Similar Companies

Sana Biotechnology & 492 more

Exit Details

Public

View Kailera's full profile

Kailera got listed on Apr 17, 2026.

Click here to take a look at Kailera's IPO in detail

Kailera has raised a total funding of $1B over 2 rounds. Its first funding round was on Oct 01, 2024. Its latest funding round was a Series B round on Oct 14, 2025 for $*****. 13 investors participated in its latest round. Kailera has 14 institutional investors.

Here is the list of recent funding rounds of Kailera:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 14, 2025	4559829	Series B	8787953	7840775	5662374	9376475
Oct 01, 2024	5256605	Series A	1344108	6212712	Atlas Venture & 2 more	lyracapital.com

Access funding benchmarks and valuations. Sign up today!

View details of Kailera's funding rounds and investors

The founders of Kailera is Ron Renaud. Ron Renaud is the CEO of Kailera.

Here are the details of Kailera's key team members:

Ron Renaud: Founder & CEO of Kailera.

View details of Kailera's Founder profiles and Board Members

Kailera's employee count trend

Kailera has 181 employees as of Jul 26. Here is Kailera's employee count trend over the years:

Uncover Kailera's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kailera include Sana Biotechnology, Adocia and Assembly Biosciences. Here is the list of Top 10 competitors of Kailera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
2nd	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
3rd	Kailera 2024, Waltham (United States), Public	Developer of therapies for treating obesity and related conditions	$1B	Bain Capital Life Sciences, RTW Investments ... & 12 others	65/100
4th	Assembly Biosciences 2005, New York City (United States), Public	Developing novel antivirals to treat serious viral diseases	$700K	Avoro Capital, Armistice Capital & 3 others	65/100
5th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Humboldt Fund, 8VC & 7 others	65/100
6th	Quell 2019, London (United Kingdom), Series B	Developer of engineered regulatory T cell therapies for immune diseases	$344M	Syncona, Fidelity Investments & 17 others	64/100
7th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	New Enterprise Associates, Bay City Capital ... & 3 others	64/100
8th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Lincoln Park Capital & 8 others	64/100
9th	Kriya Therapeutics 2012, Redwood City (United States), Series D	Developer of therapeutic solutions for the treatment of diabetes	$938M	Patient Square Capital, Foresite Capital ... & 16 others	64/100
10th	Veralox Therapeutics 2017, Frederick (United States), Series B	Developer of small molecules for treating thrombosis and diabetes pathologies	$47.5M	Sanofi Ventures, T1D Fund & 13 others	63/100